Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: Edison Investment Research
Provider: GlobalData
Provider: Crystal Research Associates

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amarantus Biosciences Inc Announces Positive Efficacy Data For MANF In Nigral Delivery Neurorestoration Animal Model Of Parkinson's Disease

Wednesday, 9 Jan 2013 08:31am EST 

Amarantus Biosciences Inc announced positive preclinical efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. The data demonstrate that unlike Glial cell-Derived Neurotrophic Factor (GDNF), MANF significantly reduces behavioral deficits, increases dopaminergic (DA) nerve terminal reinnervation of the striatum, and increases dopamine concentrations in the striatum when MANF is administered directly to the substantia nigra (SNc). The data produced comparing optimal doses to the SNc of MANF = 10 ug and GDNF = 10 ug in this model indicate the following at four weeks post-treatment: 1MANF reduced behavioral deficits by 53%, whereas behavioral deficits with GDNF increased by 20%; 2MANF produced a 14.4% reinnervation of the striatum, whereas striatum innervation with GDNF was reduced by 9.9%; 3MANF increased dopamine concentrations in the striatum, whereas striatum dopamine concentrations with GDNF did not increase. 

Company Quote

0.0020 +2.53%
21 Nov 2014